Designer drugs: a medicinal chemistry perspective

  title={Designer drugs: a medicinal chemistry perspective},
  author={F. Ivy Carroll and Anita H. Lewin and S Wayne Mascarella and Herbert H Seltzman and P Anantha Reddy},
  journal={Annals of the New York Academy of Sciences},
There are numerous medicinal chemistry reports in the literature describing the pharmacological properties of thousands of narcotics, stimulants, hallucinogens, sedative‐hypnotic drugs, cannabinoids, and other psychoactive substances as well as synthetic methods for their preparations. This information, while essential for the advancement of science, has been used by clandestine chemists to manufacture and market an endless variety of analogs of so‐called designer drugs. In this review, we… 

Designer drugs: a medicinal chemistry perspective (II)

This review focuses on three compound classes identified as synthetic opioids, synthetic amphetamines, and synthetic cannabinoids and highlights the medicinal chemistry precedents utilized by clandestine laboratories to develop new NPS with increased brain penetration, longer duration of action, and greater potency.

Synthetic cannabinoids: analysis and metabolites.

Spice/K2 drugs--more than innocent substitutes for marijuana.

The current state of knowledge regarding the pharmacological properties of synthetic cannabimimetics and the prevalence and pattern of their use are surveyed, including, among others, hallucinations, psychoses with delusions, seizures, cardiovascular symptoms and acute kidney injury.

Nephrotoxic effects of designer drugs: synthetic is not better!

The misuse of these drugs should be recognized and clinicians made aware of the potential for acute nephrotoxicity as the health burden of these compounds increases.

Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids

A class of opioid agonists not structurally related to fentanyl, derived from research publications of pharmaceutical companies or patents within the United States and abroad are contributing to the

Synthetic cannabinoids: the hidden side of Spice drugs

Insight is gained into the epidemiological, pharmacological and toxicological properties of synthetic cannabinoids, aiming to provide a reliable background needed for the management of synthetic cannabinoid-related adverse effects.

New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature.

The absence of legal risks, the ease of obtaining these drugs, the moderate cost, and the availability via the Internet are the main features that attract users, but the number of intoxicated people presenting with emergencies is increasing.

Synthetic Cathinones and Cannabinoids are New Psychoactive Substances (Review)

New psychoactive substances, or designer drugs, are currently a large group of substances, primarily of synthetic origin, which are designed and come on a shadow market in circumvention of the

Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids




Structure–Activity Relationships of Classical Cannabinoids

In this chapter an overview of the more recent developments in the structure–activity relationships (SARs) of classical cannabinoids is discussed, especially the profound pharmacological effects

Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids.

Comparisons of stereoisomers of CBD and several analogs revealed a general lack of stereoselectivity for anticonvulsant and other CNS properties of this class of compounds.

Structure‐Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Drugs? a

Evidence will be presented to support the view that the pharmacology of entactogens is clearly different from other known classes of compounds.

Endocannabinoids and Their Synthetic Analogs

Synthetic ligands structurally related to AEA and 2-AG are being used to explore the structural features of the different cannabinergic proteins and have also proven to be valuable pharmacological tools for studying the physiology and biochemistry of the endocannabinoid system.

Designer drugs: how dangerous are they?

  • L. Reneman
  • Biology, Psychology
    Journal of neural transmission. Supplementum
  • 2003
Of the designer drugs, the amphetamine analogues are the most popular and extensively studied, ecstasy (3,4-methylenedioxymethamphetamine; MDMA) in particular. They are used recreationally with

Cathinone derivatives: a review of their chemistry, pharmacology and toxicology.

  • J. Kelly
  • Biology
    Drug testing and analysis
  • 2011
It can be assumed that, despite their illegal status, cathinone-related compounds will continue to be prevalent drugs of abuse for the foreseeable future.

Designer drugs: past history and future prospects.

It is likely that, as efforts to restrict the importation of natural products and prevent diversion of pharmaceuticals become more effective, the fentanyls and other synthetics will become increasingly important drugs of abuse.

Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics.

The structural features of AAIs which are important for binding to this receptor as measured by inhibition of binding of [3H]Win 55212-2 (5) are disclosed and functional activity in the mouse vas deferens is noted and used to distinguish agonists from potential antagonists.